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The Ishango Bone, an artifact estimated to be 20,000 years 
old, is thought to be an ancient form of a 29-day calendar.1 It 
may have been used to track the lunar cycle, or a woman’s 
menstrual cycle.2 Tens of thousands of years later, women still 
track their menstrual cycles, whether in digital or analog 
format. In 2014, Apple released HealthKit, a way to display 
health information for users.3 The company was widely criticized 
for not including a period tracker in HealthKit.4 The next year, 
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 1. See Claudia Zaslavsky, Women as the First Mathematicians, ISGEM 
NEWSLETTER (Int’l Stud. Group Ethnomathematics), Jan. 1992 (“Thus far the 
oldest such incised bone, discovered in southern Africa and having 29 incisions, 
goes back about 37,000 years. Now, who but a woman keeping track of her cycles 
would need a lunar calendar?”). 
 2. Id. 
 3. See Chris Welch, Apple HealthKit Announced: A Hub for All Your iOS 
Fitness Tracking Needs, VERGE (June 2, 2014, 2:10 PM), https://www.thev-
erge.com/2014/6/2/5772074/apple-healthkit-ios-8-announcement (“Apple just 
unveiled HealthKit, a new app bundled with iOS 8 that’s designed to help users 
keep better track of their personal health and fitness data.”). 
 4. E.g., Arielle Duhaime-Ross, Apple Promised an Expansive Health App, 
So Why Can’t I Track Menstruation?, VERGE (Sept. 25, 2014, 12:55 
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Apple added a period tracker.5 Three years later, in 2018, the 
FDA granted the first marketing authorization to a software 
application to help monitor fertility.6 Women’s period tracking, 
a commonplace part of women’s lives for hundreds of thousands 
of years, was not top-of-mind to a major technology company 
designing products for everyday use. 
BACKGROUND 
Although women are fifty-one percent of the United States 
population, women’s health is still largely considered a specialty 
practice. Studies in health issues as wide-ranging as pain,7 
vulvodynia,8 and cardiac disease9 show the same thing—
women’s health issues are routinely underreported, 
 
PM),https://www.theverge.com/2014/9/25/6844021/apple-promised-an-expan-
sive-health-app-so-why-cant-i-track (explaining Apple’s HealthKit can track 
blood alcohol content, height, inhaler usage, but not menstruation). 
 
 5. Press Release, Apple, Apple Previews iOS 9 (June 8, 2015), 
https://www.apple.com/newsroom/2015/06/08Apple-Previews-iOS-9/ (“iOS 9 
APIs and tools for developers include: . . . new HealthKit data points for repro-
ductive health, UV exposure, water intake and sedentary state.”). 
 6. U.S. FOOD & DRUG ADMIN., Sub. NO. DEN170052, DE NOVO CLASSIFI-
CATION REQUEST FOR NATURAL CYCLES (2018). 
 7. See, e.g., Laura Kiesel, Women and Pain: Disparities in Experience and 
Treatment, HARVARD HEALTH BLOG (Oct. 9, 2017, 10:30 AM), 
https://www.health.harvard.edu/blog/women-and-pain-disparities-in-experi-
ence-and-treatment-2017100912562 (describing studies that show women may 
suffer from chronic pain more than men); see also Diane Hoffman & Anita Tar-
zian, The Girl Who Cried Pain: A Bias Against Women in the Treatment of Pain, 
29 J. L., MED. & ETHICS13, 13–27 (2001) (“Women are more likely to seek treat-
ment for chronic pain, but are also more likely to be inadequately treated by 
health-care providers, who, at least initially, discount women’s verbal pain re-
ports and attribute more import to biological pain contributors than emotional 
or psychological pain contributors.”). 
 8. E.g., Barbara Reed et al., Prevalence and Demographic Characteristics 
of Vulvodynia in a Population-Based Sample, 206 AM. J. OBSTETRICS GYNECOL-
OGY 170.e1, 170.e5 (2012) (“Vulvodynia causes substantial pain and suffering 
for millions of women in the United States, yet the disorder remains underdi-
agnosed and inadequately treated.”). 
 9. E.g., Laxmi S. Mehta et al., Acute Myocardial Infarction in Women: A 
Scientific Statement from the American Heart Association, 133 J. CIRCULATION 
916, 916 (2016) (“Despite stunning improvements in cardiovascular mortality 
for women in the past 2 decades . . . , CHD [coronary heart disease] remains 
understudied, underdiagnosed, and undertreated in women.”). 
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underdiagnosed, and undertreated.10 This Paper highlights a 
few considerations related to digital health innovation, 
particularly artificial intelligence and machine learning, and 
women’s health. 
Historically women have been “othered”11 in both medicine 
and technology.12 When these two areas intersect, both perils 
and opportunities are heightened. One potential peril is that the 
biases inherent in the information used by programmers can be 
encoded, and magnified, by Artificial Intelligence (AI) systems.13 
Some scholars note that AI cannot easily recognize, mitigate, or 
 
 10. See, e.g., Ashley Fetters, The Doctor Doesn’t Listen to Her. But the Me-
dia Is Starting To., ATLANTIC (Aug. 10, 2018), https://www.theatlantic.com/fam-
ily/archive/2018/08/womens-health-care-gaslighting/567149/ (providing exam-
ples of women’s health and pain concerns being dismissed by doctors). 
 11. Joy L. Johnson et al., Othering and Being Othered in the Context of 
Health Care Services, 16 J. HEALTH COMMUN. 253, 253 (2004) (“Othering is a 
process that identifies those that are thought to be different from oneself or the 
mainstream, and it can reinforce and reproduce positions of domination and 
subordination.”). 
 12. For example, it was reported that Amazon’s artificial intelligence tool 
to help screen resumes for job candidates learned to be biased against women 
by using 10 years of hiring data —  those data points came from mostly men. 
See Jeffrey Dastin, Amazon Scraps Secret AI Recruiting Tool That Showed Bias 
Against Women, REUTERS (2018), https://www.reuters.com/article/us-amazon-
com-jobs-automation-insight/amazon-scraps-secret-ai-recruiting-tool-that-
showed-bias-against-women-idUSKCN1MK08G (“That is because Amazon’s 
computer models were trained to vet applicants by observing patterns in re-
sumes submitted to the company over a 10-year period. Most came from men, a 
reflection of male dominance across the tech industry. In effect, Amazon’s sys-
tem taught itself that male candidates were preferable. It penalized resumes 
that included the word ‘women’s,’ as in ‘women’s chess club captain.’ And it 
downgraded graduates of two all-women’s colleges, according to people familiar 
with the matter. They did not specify the names of the schools. Amazon edited 
the programs to make them neutral to these particular terms. But that was no 
guarantee that the machines would not devise other ways of sorting candidates 
that could prove discriminatory, the people said.”). 
 13. This suggests that women need to be, in the words of Aaron Burr in Lin 
Manuel-Miranda’s Hamilton: An American Musical, “in the room where it hap-
pens.” The Room Where It Happens, YOUTUBE (Apr. 20, 2017), 
https://www.youtube.com/watch?v=WySzEXKUSZw. 
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correct bias in its programming.14 This could lead to poor health 
outcomes for women.15 
Heart disease, which is the number one cause of death for 
women, can be used to demonstrate the potential problem.16 
Women’s heart attack symptoms are different than men’s: men 
tend to have chest pain or pressure, while women more often feel 
fatigue and indigestion.17 If, for example, a cardiology diagnostic 
AI were coded with the “traditional” [read: male] heart attack 
symptoms, it might diagnose few, if any, women. 
In oncology, IBM’s Watson has been lauded as a potential 
breakthrough for cancer care.18 Watson, a supercomputer, uses 
 
 14. See generally Aylin Caliskan et al., Semantics Derived Automatically 
from Language Corpora Contain Human-Like Biases, 356 SCIENCE 183 (2017) 
(providing a study that demonstrates that “standard machine learning can ac-
quire stereotyped biases from textual data that reflect everyday human cul-
ture”). See also Ian Johnston, AI Robots Learning Racism, Sexism and Other 
Prejudices from Humans, Study Finds, INDEPENDENT (Apr. 13, 2017, 5:30 PM), 
https://www.independent.co.uk/life-style/gadgets-and-tech/news/ai-robots-arti-
ficial-intelligence-racism-sexism-prejudice-bias-language-learn-from-humans-
a7683161.html (summarizing the Caliskan study). 
 15. See generally Erwin Loh, Medicine and the Rise of the Robots: A Quali-
tative Review of Recent Advances of Artificial Intelligence in Health, 2 BRITISH 
MED. J. LEADER 59, 61 (2018) (discussing the challenges of AI in health such as 
inherent bias in data and the open question of who is legally liable when a mis-
take in treatment is made when a physician uses AI-based methods). 
 16. See Heart Attack Symptoms in Women, AM. HEART ASS’N, 
http://www.heart.org/en/health-topics/heart-attack/warning-signs-of-a-heart-
attack/heart-attack-symptoms-in-women (last visited Apr. 3, 2020) (explaining 
that women can experience a heart attack without any chest pain). 
 17. See Mehta et. al, supra note 9 at 922 (“Sex differences in clinical presen-
tation among patients with ACS [acute coronary syndromes] are increasingly 
evident. Although most patients with AMI [acute myocardial infarction] present 
with typical chest pain or chest discomfort, women often present with atypical 
chest pain and angina-equivalent symptoms such as dyspnea, weakness, fa-
tigue, and indigestion, as illustrated in Table 1. Sex differences in clinical 
presentation have consequences for timely identification of ischemic symptoms, 
appropriate triage, and judicious diagnostic testing and management. The det-
rimental consequences for women are misdiagnosis, delayed revascularization, 
and higher AMI mortality rates.”); see also Matthaw Liakos & Puja B. Parikh, 
Gender Disparities in Presentation, Management, and Outcomes of Acute Myo-
cardial Infarction, 20 CURRENT CARDIOLOGY REP. 64, 1 (2018) (“Delays in med-
ical care and hence longer ischemic times exist in women, partly due to de-
creased awareness and lack of symptom recognition.”). 
 18. See Casey Ross & Mike Swetlitz, IBM Pitched Its Watson Supercom-
puter as a Revolution in Cancer Care. It’s Nowhere Close, STAT NEWS (Sept. 5, 
2017), https://www.statnews.com/2017/09/05/watson-ibm-cancer/ (“Breath-
lessly promoting its signature brand — Watson — IBM sought to capture the 
world’s imagination, and it quickly zeroed in on a high-profile target: cancer.”). 
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machine learning to analyze thousands of data points, faster 
than any human. These cognitive systems learn from 
experience.19 Taking people out of the equation, some would 
argue, takes out human biases.20 The program relies on 
information from Memorial Sloan Kettering, the world-
renowned cancer center, to train Watson. But that, in and of 
itself, can inject “bias into the system, because the treatment 
recommendations it puts into Watson don’t always comport with 
the practices of doctors elsewhere in the world.”21 Not everyone 
thinks this is a bad thing. “‘We are not at all hesitant about 
inserting our bias, because I think our bias is based on the next 
best thing to prospective randomized trials, which is having a 
vast amount of experience,’ said Dr. Andrew Seidman, one of the 
hospital’s lead trainers of Watson.”22 Others, however, disagree. 
Pilar Ossorio, a professor of law and bioethics at University of 
Wisconsin Law School put it bluntly, saying “What it’s going to 
be learning is race, gender, and class bias.23 We’re baking those 
social stratifications in, and we’re making the biases even less 
 
 19. See generally How to Get Started with Cognitive Technology, IBM, 
https://www.ibm.com/watson/advantage-reports/getting-started-cognitive-tech-
nology.html (last visited Apr. 5, 2020) (“First, some background. The cognitive 
era is an ongoing movement of sweeping technological transformation. The im-
petus of this movement is the emerging field of cognitive technology, radically 
disruptive systems that understand unstructured data, reason to form hypoth-
eses, learn from experience and interact with humans naturally. Success in the 
cognitive era will depend on the ability to derive intelligence from all forms of 
data with this technology. Cognitive computing is perhaps most unique in that 
it upends the established IT doctrine that a technology’s value diminishes over 
time; because cognitive systems improve as they learn, they actually become 
more valuable. This quality among others makes cognitive technology highly 
desirable for business, and many early adopters are leveraging the competitive 
advantage it affords.”). 
 20. See, e.g., Bernard Marr, The Rise of Thinking Machines: How IBM’s 
Watson Takes on the World, FORBES (Jan. 26, 2016, 2:28 AM), 
https://www.forbes.com/sites/bernardmarr/2016/01/06/the-rise-of-thinking-ma-
chines-how-ibms-watson-takes-on-the-world/#68d6f2031e43 (“The word ‘cogni-
tive’ of course implies that the system is thinking – and in a way, scary as that 
may seem at first, it is! Its processes mirror those of our own brain – accessing 
relevant data in order to come to a conclusion based on experience of what is 
likely to work. It will, however, work through this process in a far faster, more 
accurate and repeatable fashion, unhindered by emotion, fallibility of logic, or 
ego.”). 
 21. Ross & Swetlitz, supra note 18. 
 22. Id. 
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apparent and even less easy for people to recognize.”24 Watson 
has been in development since 2010 and has been programmed 
for diagnosing patients since 2012.25 In 2019, IBM announced 
bias monitors in OpenScale—a system for developers to monitor 
their AI products—as a way to help “detect and mitigate bias 
against protected attributes like sex and ethnicity . . . .”26 
Existing and developing AI systems seek to pull data from 
numerous sources, analyze it, and help provide medical 
information or recommendations.27 These require large 
computing resources, interoperable systems, and smart 
regulation. Social media is just one medium from which large 
data sets can be pulled; it already provides access to adverse 
 
 24. Id. 
 25. See The History and Future of IBM Innovation, IBM BUS. PARTNER 
NETWORK, https://www.ibmbpnetwork.com/ibm-innovation-timeline (last vis-
ited Apr. 5, 2020) (depicting an interactive timeline of IBM innovation over time 
starting in 1891). 
 26. Susannah Shattuck, Making Monitoring AI Bias a Little Easier, IBM 
THINK BLOG (June 17, 2019), https://www.ibm.com/blogs/think/2019/06/mak-
ing-monitoring-ai-bias-a-little-easier/. 
 27. The FDA has granted marketing authorization to two AI-based devices 
for detection of medical conditions. One to detect greater than mild level of dia-
betic retinopathy (2018) and one to detect wrist fractures in adult patients 
(2018). Additionally, the FDA granted marketing authorization to an AI-based 
clinical decision support software to analyze CT results to notify providers of a 
potential stroke in their patients (2018). See FDA Permits Marketing of Artifi-
cial Intelligence-Based Device to Detect Certain Diabetes-Related Eye Problems, 
U.S. FOOD & DRUG ADMIN (Apr. 11, 2018), https://www.fda.gov/news-
events/press-announcements/fda-permits-marketing-artificial-intelligence-
based-device-detect-certain-diabetes-related-eye (“The U.S. Food and Drug Ad-
ministration today permitted marketing of the first medical device to use arti-
ficial intelligence to detect greater than a mild level of the eye disease diabetic 
retinopathy in adults who have diabetes.”); see also Jennifer Bresnick, FDA 
Clears Marketing for AI Algorithm to Detect Wrist Fractures, HEALTH IT ANA-
LYTICS (May 25, 2018), https://healthitanalytics.com/news/fda-clears-market-
ing-for-ai-algorithm-to-detect-wrist-fractures (“The FDA will allow marketing 
of an artificial intelligence algorithm that can help to detect wrist fractures in 
x-ray images.”); FDA Permits Marketing of Clinical Decision Support Software 
for Alerting Providers of a Potential Stroke in Patients, U.S. FOOD & DRUG AD-
MIN  (Feb. 13, 2018), https://www.fda.gov/news-events/press-announce-
ments/fda-permits-marketing-clinical-decision-support-software-alerting-pro-
viders-potential-stroke (“Today, the U.S. Food and Drug Administration 
permitted marketing of the Viz.AI Contact application, a type of clinical deci-
sion support software designed to analyze computed tomography (CT) results 
that may notify providers of a potential stroke in their patients.”). 
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event information,28 epidemiological trends,29 and direct access 
to subsets of patients.30 Many consumers and patients are 
voluntarily publishing their data by tweeting it, posting it, and 
joining research networks.31 Other potential data sets include 
coordinated registry networks and insurance claims data. 
At the same time, the average person has direct access to 
more health-related data than ever before: published articles, 
peer-reviewed scientific papers, and personalized direct-to-
consumer advertising.32 Conversely, false, misleading, and 
incomplete information abounds, and can be easily spread 
through social media.33 This direct access to health information, 
 
 28. See Abeed Sarker et al., Utilizing Social Media Data for Pharmacovig-
ilance: A Review, 54 J. BIOMEDICAL INFORMATICS 202, 203 (2015) (discussing 
the FDA’s Adverse Event Reporting System). 
 29. See Lauren E. Charles-Smith et al., Using Social Media for Actionable 
Disease Surveillance and Outbreak Management: A Systematic Literature Re-
view, 10 J. PLOS ONE 1, 1 (2015) (“Research studies show that social media 
may be valuable tools in the disease surveillance toolkit used for improving pub-
lic health professionals’ ability to detect disease outbreaks faster than tradi-
tional methods and to enhance outbreak response.”). 
 30. E.g., Allison M. Burton-Chase et al., The Use of Social Media to Recruit 
Participants with Rare Conditions: Lynch Syndrome as an Example, 6 J. MED. 
INTERNET RES. RES. PROTOCOLS (2017) (providing an example of a study that 
uses social media to recruit patients with Lynch Syndrome); Christopher-Paul 
Milne & Wendi Ni, The Use of Social Media in Orphan Drug Development, 39 
J. CLINICAL THERAPEUTICS 2173, 2177 (2017) (“Besides site selection, compa-
nies can utilize social media to efficiently reach potential patients to accelerate 
patient recruitment.”). 
 31. PatientsLikeMe, a for-profit research network, has more than 600,000 
patients, with more than 2,800 conditions, has amassed more than 43 million 
data points and published more than 100 studies. See PatientsLikeMe Homep-
age, PATIENTSLIKEMe https://www.patientslikeme.com/ (last visited Apr. 5, 
2020). 
 32. Caitlin Dewey, 98 Personal Data Points that Facebook Uses to Target 
Ads to You, WASHINGTON POST (Aug. 19, 2016, 10:13 AM), https://www.wash-
ingtonpost.com/news/the-intersect/wp/2016/08/19/98-personal-data-points-
that-facebook-uses-to-target-ads-to-you/?utm_term=.f410525d5f65 (explaining 
that Facebook advertisers target consumers based on location, age, gender, ed-
ucation level, and many other indicators). 
 33. See generally Luigi Lavorgna et al., Fake News, Influencers and Health-
Related Professional Participation on the Web: A Pilot Study on a Social-Net-
work of People with Multiple Sclerosis, 25 J. MULTIPLE SCLEROSIS & RELATED 
DISORDERS 175, 175–178 (2018) (speculating that the presence of “neurologists 
and psychologists supervising the information flow might have contributed to 
reduce the risk of fake news spreading”); Questioning Reliability Assessments 
of Health Information on Social Media, 105 J. MED. LIBR. ASS’N 61, 61 (2017) 
(examining “assessments of the reliability of online health information re-
trieved through social media to ascertain whether health information accessed 
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called disintermediation, arguably takes the healthcare provider 
out of the role of learned intermediary to help guide a patient. 
However, disintermediation can work the other way, where 
patients can directly report adverse events, symptoms, 
diagnoses, or other relevant health care information.34 
Disintermediation may reduce some types of bias by allowing the 
data systems to directly collect information from patients; 
however, satisfied patients often have little reason to provide 
feedback, leading reporting to be overwhelmingly negative.35 
This patient-generated health data, or patient-reported 
outcomes, might help lead to a healthcare system that better 
listens to women. Women who are told, for example, they have 
not had a heart attack, may be able to advocate for themselves 
with data gathered from a wearable device. However, if this 
disintermediation does not overcome bias, but rather reaffirms 
it, it will continue on to other women, leaving them under-
diagnosed and under-treated. 
REGULATION 
The federal government’s role in regulating medical 
products has a long history, focused on consumer protection. The 
FDA seeks to ensure not only that medical products are likely to 
be safe and effective, but that new products have a predictable 
 
or disseminated through social media should be evaluated differently than 
other online health information”); Przemyslaw M. Waszak et al., The Spread of 
Medical Fake News in Social Media— The Pilot Quantitative Study, 7 J. 
HEALTH POL’Y & TECH. 115, 117 (2018) (“40% of the most frequently shared 
links contained text we classified as fake news.”). 
 34. See Marlene Beggelman, Why Do We Doctors So Often Fail to See Symp-
toms are Drug Side Effects?, WBUR (Dec. 30, 2016), http://www.wbur.org/com-
monhealth/2016/12/30/doctors-side-effects-medication (recognizing physicians 
are unable to attribute symptoms to medication side effects and, therefore, sug-
gesting that patient stories about reported side effects deserve consideration); 
see also Northwestern University, Why Women Quit Breast Cancer Drugs Early: 
Side Effects are So Bad Women End Treatment and Risk Return of Cancer, 
Study Finds, SCIENCEDAILY (Dec. 12, 2011), https://www.sciencedaily.com/re-
leases/2011/12/111209171936.htm (describing a study that shows that doctors 
underestimated the side-effects of a breast cancer therapy at least in part be-
cause women often did not want to share their side effects with their doctors ). 
     35. See, e.g., Giuseppe Verlento et al., Asthmatics and Ex-Smokers Respond 
Early, Heavy Smokers Respond Late to Mailed Surveys in Italy, 104 Respira-
tory Medicine 172 (2010) (detailing a study in which self-reporting lead to a 
statistical biasing effect because the response rate was significantly higher for 
respondents with certain chronic respiratory diseases).  
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pathway to market.36 This, in fact, encourages innovation, which 
furthers patient health.37 Federal and state regulations exist to 
protect patient health as well as privacy. Additionally, 
regulation that addresses the need for data system 
interoperability and correction for bias in clinical studies have 
been enforced for years. Regulation can help, in part, to control 
or mitigate some biases—like gender—in the development of 
medical evidence. 
Legislative mandates and regulatory requirements have 
increased the representation of women in clinical trials. After a 
1992 GAO report on women and prescription drugs,38 the FDA 
published a guidance titled “Guideline for Study and Evaluation 
of Gender Differences in the Clinical Evaluation of Drugs”, 
which included the “FDA’s expectations on inclusion of women 
in drug development.”39 Congress passed a law that required 
NIH to ensure that women and minorities were appropriately 
included in NIH-funded trials.40 In 2014, the FDA issued a final 
guidance on the Evaluation of Sex Specific Data in Medical 
Device Clinical Studies, the purpose of which was to encourage 
“appropriate enrollment by sex in clinical studies of devices, and 
 
     36. See A HISTORY OF MEDICAL DEVICE REGULATION & OVERSIGHT IN THE 
UNITED STATES, U. S. FOOD & DRUG ADMIN., https://www.fda.gov/medical-de-
vices/overview-device-regulation/history-medical-device-regulation-oversight-
united-states 
 37. See Scott Gottlieb, COMM’R OF FOOD AND DRUGS, U.S. FOOD AND DRUG 
ADMIN., MEDICAL DEVICE INNOVATION CONSORTIUM 2018 ANNUAL PUBLIC FO-
RUM: ADVANCING OUR PARTNERSHIP FOR PATIENT SAFETY AND MED TECH IN-
NOVATION (Sept. 5, 2018) (“We’re focused on ensuring efficient, timely access to 
new technologies; but also to making sure that the same policies that promote 
these goals also make our regulatory programs more rigorous, more science 
based, and more effective. Promoting product safety is a touchstone for all of 
our new policy efforts.”). 
 38. See generally U.S. GEN. ACCOUNTING OFFICE, FDA NEEDS TO ENSURE 
MORE STUDY OF GENDER DIFFERENCES IN PRESCRIPTION DRUGS TESTING (Oct. 
1992) (emphasizing the need to study how women respond differently than men 
when approving prescription drugs). 
 39. Guideline for the Study and Evaluation of Gender Differences in Clini-
cal Evaluation of Drugs, 58 Fed. Reg. 39,406 (July 22, 1993). 
 40. See National Institutes of Health Revitalization Act of 1993, Pub. L. No. 
103-43, § 492B, 107 Stat. 122 (1993) (“SEC. 492B. (a) REQUIREMENT OF IN-
CLUSION. -(1) IN GENERAL.- In conducting or supporting clinical research 
for purposes of this title, the Director of NIH shall, subject to subsection (b), 
ensure that- (A) women are included as subjects in each project of such research; 
and (B) members of minority groups are included as subjects in such research.”). 
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that data from such studies is appropriately analyzed by sex.”41 
In 2012, Congress required that the FDA address the inclusion 
of demographic subgroups in clinical trials.42 The law required 
the FDA to publish a report and action plan regarding the 
availability of data on demographic subgroup analysis.43 These 
legislative and regulatory requirements started to address 
potential bias in the health research. These requirements could 
similarly apply, as appropriate, to digital health and AI health 
systems to mitigate the coding of bias. 
The Health Insurance Portability and Accountability Act of 
1996 (HIPAA)44 is a key medical privacy law. HIPAA security 
and privacy protections apply only to covered entities—health 
plans, health care providers, health care clearinghouses—and 
business associates of covered entities.45 However, health data 
not subject to HIPPA may not be held to federal legal protections 
of privacy,46 laws can also differ by state.47 When apps interface 
 
 41. U.S. FOOD AND DRUG ADMIN., EVALUATION OF SEX-SPECIFIC DATA IN 
MEDICAL DEVICE CLINICAL STUDIES: GUIDANCE FOR INDUSTRY AND FOOD AND 
DRUG ADMINISTRATION STAFF, 1 (Aug. 2014). 
 42. See Food and Drug Administration Safety and Innovation Act, Pub. L. 
No 112-144, § 907, 126 Stat. 993, 1092 (July 9, 2012) (“ . . . the Secretary 
shall . . . shall publish . . . a report . . . addressing the extent to which clinical 
trial participation and the inclusion of safety and effectiveness data by demo-
graphic subgroups . . . is included in applications submitted to the Food and 
Drug Administration.”). 
 43. See Id. at § 907(b) (explaining that the FDA must put together an action 
plan “to improve the completeness and quality analyses on demographic sub-
groups in summaries of product safety”). 
 44. Health Insurance Portability and Accountability Act, Pub. L. 104–191, 
110 Stat. 1936 (Aug. 21, 1996). 
 45. See Are You a Covered Entity?, CTRS FOR MEDICARE AND MEDICAID 
SERV., https://www.cms.gov/Regulations-and-Guidance/Administrative-Simpli-
fication/HIPAA-ACA/AreYouaCoveredEntity.html. 
 46. See The Disruptor Series: Health Care Apps: Hearing Before the Sub-
comm. On Commerce, Manufacturing, and Trade of the H. Comm. on Energy 
and Commerce, 114th Cong. (2016) (opening remarks for H. Energy and Com-
merce Subcomm. Hearing on Health Care Apps) (“However, the most disruptive 
health apps are those that are patient-facing. These create a direct app-patient 
“relationship” that lacks professional intermediation and, as a result, tradi-
tional regulation of safety, quality, and confidentiality . . . . Most mobile health 
apps (particularly the more disruptive patient-facing examples) are not subject 
to HIPAA privacy and security rules leaving patient wellness and health data 
woefully unprotected.”). 
 47. See DEP’T OF HEALTH AND HUMAN SERV., NAT’L COMM. ON VITAL 
HEALTH AND STATISTICS: MEETING OF PRIVACY, CONFIDENTIALITY AND SECU-
RITY SUBCOMM. (Nov. 28, 2017) (“So, here are some of the primary entities of 
concern that I think you ought to be looking at. There are still a few providers 
2020] NOT INTELLIGENT 293 
 
directly with health data rather than an electronic health record 
or doctor, the app developer may offer no privacy protections at 
all.48 
The data gathered through electronic records, registries, 
and other media could have more value if they are in a format 
that allows them to be aggregated and analyzed.49 This 
standardization and ensuing interoperability might be 
mandated by law,50 agreed upon by participating bodies, or 
incentivized in other ways. For example, the FDA published a 
rule in 2013 requiring the use of the Unique Device Identifier 
(UDI) on medical devices.51 The use of UDI can help track 
 
who aren’t HIPAA covered. There is all of the social media, as Frank described. 
There is web search history, such as somebody visiting websites like WebMD. 
There are wearables. There are the remnants of the personal health record in-
dustry outside of the tethered ones. There is a whole range of ones of storage 
that either may or may not be social media that people can import their data 
into, like all of those calorie counters and MapMyRun app available online. 
There is all of the recreational genetics. Some of the data from some of these 
goes into registries and then there are registries all over the place. So, why are 
non-HIPAA covered entities a problem? Well, they might have, in fact, health 
information that is as detailed and as sensitive as what HIPAA-covered entities 
have. They may be getting their PHI actually from HIPAA-covered entities, 
when patients don’t realize that their PHI has been transferred and is no longer 
HIPAA-protected. The protections that do exist, as Frank outlined, primarily 
the FTC, there also are some state laws relevant here, are uneven. The privacy 
policies and the terms of conditions that these entities have are all over the 
map. They are very hard to find. Critical pieces of information may be buried in 
the terms and conditions. The downstream uses of these data, once they get into 
some of these entities, particularly if they are deidentified, but even in some 
cases when they are identified, may be very difficult to trace.”). 
 48. See generally Sarah. R. Blenner et al., Privacy Policies of Android Dia-
betes Apps and Sharing of Health Information, 351 J. AM. MED. ASS’N 1051 
(2016). 
 49. For example, ACOG embarked on a multi-year, multi-stakeholder ef-
fort to standardize obstetric definitions for the purposes of its registries. See 
current definitions at https://www.acog.org/practice-management/health-it-
and-clinical-informatics/revitalize-obstetrics-data-definitions. 
 50. See 21st Century Cures Act, Pub. L. 114-255, § 4003, 130 Stat. 1033 
(Dec. 13, 2016) (“The term ‘interoperability’, with respect to health information 
technology, means such health information technology that— (A) enables the 
secure exchange of electronic health information with, and use of electronic 
health information from, other health information technology without special 
effort on the part of the user; (B) allows for complete access, exchange, and use 
of all electronically accessible health information for authorized use under ap-
plicable State or Federal law . . . ”). 
 51. See Unique Device Identification System, 78 Fed. Reg. 58,786 (Sept. 24, 
2013) (to be codified at 21 C.F.R. pt. 16). 
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products and allow a more reliable adverse event report.52 In this 
way, large data sets can report the same information—via the 
UDI—allowing researchers and regulatory bodies to track 
emerging health events. 
Registries, mentioned above, can be a wonderful way to 
gather data. However, they are expensive and can take time and 
effort to gather longitudinal data.53 Additionally, many 
registries are established by disease state or device-type, 
meaning that a large amount of data are not captured. And there 
may not be any standard way to capture gender/sex data.54 
In late 2019, the FDA announced it would launch a program 
to study the sex and gender differences in reactions to medical 
devices—both for safety and effectiveness.55 The first step of the 
plan as released in 2019 was to review and standardize sex and 
gender specific data collection for medical devices.56 While this 
is a reasonable first step, it is long overdue. As far back as 2014, 
the FDA announced that it would enhance its systems for 
collecting and analyzing “diverse clinical information.”57 This is 
not to lay blame at the feet of the FDA—the industry and 
 
 52. See Are You Ready for UDI?: Unique Device Identification for Medical 
Devices, GS1 (2015) https://www.gs1.org/sites/default/files/docs/healthcare/a3-
ready_for_udi-bd.pdf (“The implementation of UDI can enhance patient safety 
and improve efficiency in the healthcare supply chain. The system is expected 
to unambiguously identify medical devices throughout the global supply chain 
by providing precise information for healthcare professionals, thereby providing 
a secure global supply chain allowing for more accurate reports of adverse 
events, more effective management of medical device recalls and reduction of 
medical errors.”). 
     53.    See, e.g., REGISTRIES FOR EVALUATING PATIENT OUTCOMES: A USER'S 
GUIDE (Richard E. Gliklich & Nancy A. Dreyer eds., 3rd ed. 2014) 
https://www.ncbi.nlm.nih.gov/books/NBK208643/. 
     54.    See, e.g., Madeline B. Deutsch & David Buchholz, Electronic Health 
Records and Transgender Patients—Practical Recommendations for the Collec-
tion of Gender Identity Data, 30 J. GEN. INTERN. MED. 843 (2015) (“Barriers to 
standardization may include lack of specific functionality in a given product, 
limited understanding of gender identity. . . issues among EHR implementa-
tion teams, competing institutional priorities, or a lack of institutional will to 
address a new and confusing issue.”).  
 55. See U.S. FOOD AND DRUG ADMIN. FDA-2019-N-3804, CENTER FOR DE-
VICES AND RADIOLOGICAL HEALTH: HEALTH OF WOMEN PROGRAM STRATEGIC 
PLAN (Sept. 2019). 
 56. See Id. at 13. 
 57. U.S. FOOD AND DRUG ADMIN., FDA ACTION PLAN TO ENHANCE THE 
COLLECTION AND AVAILABILITY OF DEMOGRAPHIC SUBGROUP DATA (Aug. 2014). 
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researchers doing these studies do not consistently gather and 
report sex and gender differences. 
CONCLUSION 
Much progress has been made in the past twenty years 
when it comes to women’s health, but issues of inclusion have 
not disappeared. Numerous government agencies continue to 
work on issues of gender bias and subsequent biased reporting. 
Relevant regulatory requirements may apply to some digital 
health tools, including AI, to help protect patients. Disclosure of 
information that can help screen for or provide transparency 
about potential issues of bias, as well as other patient 
protections, may also help patients and providers choose the 
appropriate tools. 
Patients, regulators, providers, and industry must all play 
a role in ensuring that bias is not incorporated, and reinforced, 
in the burgeoning field of digital health and artificial 
intelligence. Legislation and regulations are necessary, but not 
sufficient, to overcome biases. There are growing technological 
solutions that provide an outside check on AI, to ensure that it 
is not biased. A growing reliance on AI is in the cards for 
healthcare—it is imperative that the technology take us beyond 
the Bronze Age. 
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